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feeding or satiation or to assess the
ability of glucose to alter neuronal
activity or the release of peptides
(Levin et al., 2004; Parton et al., 2007).
Such nonphysiological glucose levels
provide little useful evidence foraphys-
iological role of glucose in vitro or
in vivo in the regulation of neuronal
function or energy and glucose ho-
meostasis. Thus, after more than 50
years, we are still in search of a direct
link between neuronal glucose sensing
and the physiological regulation of
food intake and other facets of energy
and glucose homeostasis. However,
the Claret et al. (2007) and Parton
et al. (2007) studies do point to im-
portant glucose-sensing-independent
roles for both AMPK and the KATP
channel in POMC neurons in the con-
trol of these physiological processes,
which should be the focus of future
studies in this field.
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Loss of estrogen atmenopause causes osteoporosis inmanywomen, but estrogen’s relevant cellular
target in this process has remained unclear. In a recent study inCell, Kato and colleagues (Nakamura
et al., 2007) selectively ablate estrogen receptor a in osteoclasts and demonstrate that estrogen
directly induces osteoclast apoptosis.Estrogen plays a central role in the
control of bone strength, and its loss
at menopause causes osteoporosis
in millions of women. In healthy indi-
viduals, bone mass is maintained by
the balanced activity of bone-forming
osteoblasts and bone-resorbing oste-
oclasts. These two cell types, although
derived from mesenchymal and he-
matopoietic precursors, respectively,
affect each other’s differentiation and
activity. In addition, bone, particularly
the trabecular component closely as-
sociated with bone marrow, is a rich
microenvironment in which many cell
types have the opportunity to influence
osteoblast/osteoclast dynamics.254 Cell Metabolism 6, October 2007 ª2Osteoporosis, at the outset, is a dis-
ease of increased bone turnover in
which the bone-resorbing activity of
osteoclasts outpaces the bone-form-
ing activity of osteoblasts, leading to
loss of predominantly trabecular
bone. Both of these cell types are
reported to respond to estrogen.
However, many studies suggest that
bone’s response to estrogen with-
drawal is at least in part mediated by
a network of inflammatory and osteo-
clastogenic cytokines including TNFa
and IL-1, released by stromal/osteo-
blast lineage cells and T cells
(Figure 1A) (Clowes et al., 2005).
Thus, the critical estrogen target cell007 Elsevier Inc.has been a matter of considerable
debate.
Most estrogenic effects are medi-
ated by the nuclear hormone receptor
transcription factors estrogen receptor
a and b (ERa and b); some actions are
attributed to an unidentified mem-
brane receptor that signals through
JNK or ERK kinases. Mice lacking
ERa, ERb, or both do not show the
expected low bone mass but have
abnormally high levels of either testos-
terone or estradiol, leading to con-
founding effects on the androgen
receptor (Sims et al., 2002). Further
studies in which sex steroid levels
were controlled by gonadectomy and
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PreviewsFigure 1. Models of Osteoclast Activation
(A) Hypothetical model of immune regulation of postmenopausal osteoporosis, in which osteo-
blast lineage cells (OBs) are the primary estrogen target. Decreased levels of estrogen lead to
increased production of the cytokine IL-7 by OBs, promoting proliferation of T cells and their
secretion of both TNF and RANKL. TNF stimulates OBs to increase their synthesis of RANKL,
which leads to osteoclast (OC) differentiation and activation. TNF also acts directly on osteoclast
progenitors (pOCs), synergizing with RANKL for OC differentiation. Additional pro-osteoclasto-
genic cytokines and growth factors are also expressed by T cells and other peripheral blood
mononuclear cells.
(B) Model of direct estrogen action on osteoclasts, based on Nakamura et al. (2007). Estrogen, act-
ing via ERa, causes upregulation of FasL by pOCs and/or OCs. Since these OC lineage cells also
express Fas, increased FasL levels cause apoptosis, limiting the number and life span of OCs. In
the absence of estrogen, FasL expression is lost, and OC life span is prolonged. Surviving OCs
stimulate osteoblasts to form more bone (via poorly defined factors), but the resorptive effect is
dominant. In both (A) and (B), the net effect of estrogen loss is increased by osteoclastic bone
resorption that outpaces osteoblastic bone formation.estrogen treatment suggest that ERa
plays the dominant role in regulating
bone mass in both males and females
(Sims et al., 2003). However, the artifi-
cial manipulation of sex steroids and
the global deletion of the receptors
left open many questions about the
direct impact of estrogen on bone
cells.
In a recent issue of Cell, Kato and
colleagues (Nakamura et al., 2007)
employ an elegant approach to ana-
lyze the direct effect of estrogen on
osteoclasts. Taking advantage of a
previously described conditional ERa
allele (Dupont et al., 2000), the authors
inserted the Cre recombinase into
the cathepsin K (Ctsk) locus, allowing
them to specifically delete ERa during
osteoclastogenesis. These ERaDOc/DOc
mice have normal levels of sex ste-
roids, removing a major factor con-
founding previous approaches. Adult
female, but not male, ERaDOc/DOc
mice displayed high bone turnover
osteoporosis, with decreased trabec-ular bone mass, increased osteoclast
numbers, and increased bone forma-
tion. These ERaDOc/DOc mice, there-
fore, seem to mimic human post-
menopausal osteoporosis to a greater
extent than previous mouse models.
The abrupt loss of estrogen following
ovariectomy caused loss of trabecular
bone and increased osteoclast num-
bers in wild-type mice, but not in
ERaDOc/DOc mice, despite apparently
intact induction of TNFa and IL-1a.
Additionally, although estrogen treat-
ment following ovariectomy effectively
reversed trabecular bone loss in con-
trols, similar treatment of ERaDOc/DOc
mice did not increase bone mass.
Thus, despite the presence of estro-
gen-responsive osteoblasts, T cells,
and other potential targets, acute
manipulation of estrogen levels has
no effect on trabecular bone when
osteoclasts are unable to respond
directly to estrogen.
Several groups have reported direct
induction of osteoclast apoptosis byCell Metabolismestrogen in vitro, but whether this
occurs in vivo was left unclear. Naka-
mura et al. (2007) find apoptotic,
FasL-expressing osteoclasts in the
bones of estrogen-treated ovariecto-
mized wild-type mice. Osteoclasts
lacking ERa do not upregulate FasL,
either in vivo or in vitro, and do not
undergo apoptosis following estrogen
treatment. Fas, the death receptor
required for an apoptotic response to
FasL, is also expressed by osteoclasts
but is not regulated by estrogen.
Thus, estrogen-mediated upregulation
of FasL appears to control osteoclast
life span in an autocrine manner
(Figure 1B). Although in most in-
stances Fas and FasL are expressed
in different cells, apoptosis of single
T cells expressing both proteins has
been described (Brunner et al., 1995).
However, the mechanism by which
Fas and FasL expressed by the same
cell might interact remains unknown.
One puzzling finding is that, in the
ovariectomized ERaDOc/DOc mice,
TNF levels are increased, but there is
no effect on osteoclast numbers or
bone mass. TNF is a potent osteoclas-
togenic factor that induces RANKL on
osteoblast lineage cells and also acts
directly on osteoclasts and their pre-
cursors. It is not clear why TNF and
the RANKL it induces locally do not
act on ERa-deficient osteoclast line-
age cells to enhance bone resorption,
since the response to these cytokines
is independent of estrogen. Are the
ERaDOc/DOc mice already at the upper
limit of their osteoclastogenic response
prior to ovariectomy?
In isolation, the data derived from
the osteoclast-specific deletion of
ERa convincingly indicate that the os-
teoclast is the key estrogen target for
the maintenance of bone mass. How-
ever, it is difficult to ignore myriad
other studies in both mice and humans
suggesting that the immune system
and a host of inflammatory cytokines
are activated upon estrogen with-
drawal, with adverse effects on bone
mass (Clowes et al., 2005). In many
studies using genetically modified
mice, removal of response to a single
factor (such as TNF, IL-6, IL-7, or IL-
11) has been found to block bone
loss following ovariectomy. It is diffi-
cult to envision how each factor could6, October 2007 ª2007 Elsevier Inc. 255
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Previewsexert such a dominant effect when
the normal physiological response in-
volves upregulation of so many dis-
tinct factors. Most investigators have
concluded that several cytokines
have unique yet interconnected roles
in the pathogenesis of osteoporosis.
Similarly, although removal of ERa
only from the osteoclast ablates the
response to changes in estrogen, it
is likely that deleting the receptor
from other estrogen-responsive cells
will reveal additional critical cellular256 Cell Metabolism 6, October 2007 ª2targets for estrogen, generating a
more complete picture of the complex
process of postmenopausal bone
loss.
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